# A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Source: https://onco.cc/trials/nct07023315/  
OnCo record `nct07023315` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cadonilimab in gastric & gastro-oesophageal junction cancer, run by Akeso, now recruiting.

## Summary

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma is a phase 3 interventional study registered as NCT07023315 by Akeso, with 760 participants planned, started 2025-08-14 and due to reach its primary completion in 2029-07. Interventions recorded: Cadonilimab, SOX chemotherapy and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07023315
- Phase: 3
- Setting: A Randomized, Double-blind, Phase III Clinical Study Comparing the Efficacy and Safety of Cadonilimab Plus Oxaliplatin and Tegafur-Gimeracil-Oteracil Potassium (SOX) Versus Placebo Plus SOX as Perioperative Treatment for Patients With Resectable Gastric and Gastroesophageal Junction (G/GEJ) Adenocarcinoma
- Sponsor: Akeso
- Enrolled: 760

## Sources

- ClinicalTrials.gov NCT07023315: https://clinicaltrials.gov/study/NCT07023315

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct07023315.json